Foot-Blister and Chafing Care in 69 Ultramarathon Runners

November 12, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional activity, training or occupational setting. It is not a patient, diagnosis, before-and-after image, institutional endorsement or Dr. Arsy #003 treatment result.

Reader question: What did this exact study measure, in whom, with which comparator and timepoint—and which conclusions would go beyond its evidence?

Study snapshot

Study element	Reported detail
Population	All 69 starters in the 2010 Al Andalus 219-km, five-day ultramarathon stage race.
Design	Observational event study of clinical encounters with health professionals.
Comparator	Reasons for consultation within the same race; no non-running control.
Timepoint	Five race days totaling 219 km.
Key result	Thirty-nine runners (56.5%) had a medical problem during 99 encounters. Foot blisters accounted for 33.3% of encounters and chafing for 9.1%.
Funding/conflict context	Funding and author-conflict details were not reported in the accessible PubMed abstract.

What was actually measured?

Thirty-nine runners (56.5%) had a medical problem during 99 encounters. Foot blisters accounted for 33.3% of encounters and chafing for 9.1%.

The paper reports encounter shares and the number of runners seen, which are different denominators. Repeated visits mean encounter percentages are not runner prevalence.

The denominator defines the claim. People, visits, infections, episodes, isolates, feet and blisters are different analytic units. A percentage or rate using one unit cannot be silently rewritten as the percentage of people affected.

What the result does not prove

One race, one year and care-seeking documentation limit generalizability. Minor self-treated problems may be missed, and the abstract provides no uncertainty intervals.

Association and timing do not automatically prove individual causation. Footwear, surfaces, climate, ultraviolet exposure, hygiene, protective equipment, training load, prior conditions, referral patterns and access to care may change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors’ conclusions, this interpretation or any product.

Keep the condition categories separate

Dryness, friction injury, sunburn, dermatitis, sensitization, fungal disease and bacterial infection are not interchangeable. A moisturizer may support hydration and the moisture barrier, but it does not diagnose infection, prevent ultraviolet injury, replace medical evaluation or substitute for activity-specific prevention.

Persistent spreading redness, drainage, fever, severe pain, rapidly worsening symptoms, a suspected contagious outbreak or major loss of function warrants prompt professional assessment. Clinicians may need microscopy, culture, patch testing, skin-prick testing or other targeted evaluation depending on the question.

Activity details worth documenting

What surface, footwear, sock, glove, mat, pool, boat, uniform, animal, climate or training load preceded the change?
Where did the problem begin, and did it change during rest, travel, deployment, competition or a different facility?
Were towels, clothing, footwear, razors, equipment or showers shared, and how were high-touch surfaces cleaned?
How often was skin wet, occluded, rubbed, heated, chilled or exposed to sun?
Did the problem alter sleep, pace, attendance, training, competition, work safety or duty status?

Prevention comes before cosmetic care

Prevention should match the hazard: well-fitted and broken-in equipment, task-appropriate textiles, friction management, clean personal gear, facility hygiene, prompt showering, ultraviolet protection and timely clinical assessment. No single intervention prevents every diagnosis.

Do not share personal skin products during an outbreak and do not test workplace, sport or environmental materials directly on skin. Follow occupational-health, sports-medicine, public-health and facility instructions for contagious or exposure-related conditions.

Primary research and authoritative guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, infection, blisters, sunburn or sensitization; relieves pain or itch; neutralizes environmental exposures; is appropriate for every person; or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace, sports, military, maritime, animal-exposure or infection-control determination.

← Back to Doctor's Notes